Business
Media
Conferences
Publications
CME/CE
Resources
Subscribe

Erik Goluboff, MD, MBA, Tyra Biosciences, Inc.

Affiliations:

Tyra Biosciences, Inc.

Carlsbad, CA, USA

Articles by Erik Goluboff, MD, MBA, Tyra Biosciences, Inc.

Oral Selective FGFR3 Inhibition in Urothelial Carcinoma: Opportunities in Intermediate Risk Non-Muscle Invasive Bladder Cancer and Low Grade Upper Tract Urothelial Carcinoma

ByErik Goluboff, MD, MBA, Tyra Biosciences, Inc.

March 30th 2026

Latest Updated Articles

Trending on Urology Times

TULSA preserves penile length vs robotic prostatectomy in CAPTAIN trial

The UroOnc Minute: Optimizing Patient Follow-Up in Urologic Oncology, With Jason Hafron, MD

Published data support PSMA-PET–guided selection for 177Lu-rosopatamab tetraxetan in mCRPC

FDA grants priority review to talazoparib plus enzalutamide for HRR gene-altered mCSPC

KEYNOTE-B15 data on enfortumab vedotin plus pembrolizumab in MIBC published in NEJM